Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

This study has been completed.
Sponsor:
Information provided by:
Myrexis Inc.
ClinicalTrials.gov Identifier:
NCT01097070
First received: March 23, 2010
Last updated: March 30, 2010
Last verified: March 2010

March 23, 2010
March 30, 2010
November 2008
January 2009   (final data collection date for primary outcome measure)
Measure bevirimat blood plasma concentrations to calculate the pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life when bevirimat is administered as 2 x 100 mg tablets BID, 3 X 100 mg tablets QD, 4 X 100 mg tablets QD for 15 days [ Time Frame: 16 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01097070 on ClinicalTrials.gov Archive Site
Measure bevirimat blood plasma concentrations following the administration of bevirimat 2 X 100 mg, 3 x 100 mg, or 4 x 100 mg tablets after a standardized meal. The pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life will be calculated. [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
A Phase II Multicenter, Open-label, Randomized, Parrallel Group Study to Assess the Pharmacokinetics of Bevirimat (BVM) 100 mg Tablets Administered to HIV-1 Positive Patients for 15 Days

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV-1 Infection
Drug: Bevirimat
Other Name: MPC-4326
  • Experimental: Bevirimat 200 mg twice daily, 15 days
    Intervention: Drug: Bevirimat
  • Experimental: Bevirimat 300 mg once daily, 15 days
    Intervention: Drug: Bevirimat
  • Experimental: Bevirimat 400 mg once daily, 15 days
    Intervention: Drug: Bevirimat
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
January 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have documentation of HIV-1 infection in their medical records (documentation of any prior plasma viremia is acceptable).
  • Have a CD4+ lymphocyte count >/= 100 cells/mm3.
  • Have a screening plasma HIV-1 RNA value, measured by the Roche Amplicor assay, of <400 copies/mL.
  • Be receiving an ARV therapy regimen containing at least 3 drugs which has been unchanged for at least 8 weeks prior to screening, and which is to be continued through Day 15 of the study.
  • Be informed of the nature of the study and provide written informed consent.
  • Be legally competent and able to communicate effectively with study personnel.
  • Be able and willing to comply with outpatient visits.

Exclusion Criteria:

  • Presence of any acute illness within 14 days prior to study entry.
  • Presence of any AIDS-related opportunistic infection (Category C according to the CDC Classification System for HIV-1 Infection, 1993 Revised Version) that is unstable in the Investigator's opinion or diagnosed in the 30 days prior to study entry.
  • Patients who are, in the opinion of the Investigator, unable to comply with the dosing schedule and protocol evaluations.
  • Patients with malabsorption syndromes affecting drug absorptions (e.g. Crohn's disease, chronic pancreatitis).
  • Patients with systolic blood pressure < 90 mmHg or > 160 mmHg or diastolic blood pressure < 50 mmHg or > 110 mmHg.
  • A history of seizures (excluding pediatric febrile seizures) or current administration of prophylactic anti-seizure medication for the indication of seizures or seizure-related conditions.
  • A history of cerebrovascular accident (CVA) or transient ischemic attacks (TIA).
  • Patients who have received radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to first dose of study drug.
  • Patients who have received treatment with immunomodulating agents such as IL-2, alpha-interferon, beta-interferon, or gamma-interferon within 4 weeks prior to first dose of study drug.
  • Receipt of an investigational drug or product, or participation in a drug study within a period of 30 days prior to receiving study medication.
  • Bupropion-containing products require at least a 14-day washout period and will not be approved for co-administration.
  • Rifampin or other rifamycin products require at least a 28-day washout period and will not be approved for coadministration.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01097070
Bevirimat Study 206
No
Andrew Beelen, MD., Study Director, Myriad Pharmaceuticals, Inc.
Myrexis Inc.
Not Provided
Study Director: Andrew Beelen, MD Myrexis Inc.
Principal Investigator: Jacob P Lalezari, MD Quest Clinical Research
Principal Investigator: Gary J Richmond, MD, PA
Principal Investigator: Melanie A Thompson, MD AIDS Research Consortium of Atlanta
Principal Investigator: Calvin J Cohen, MD, MSc Community Research Initiative of New England
Myrexis Inc.
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP